Research Topics
Genomes and Genes
| Matthias G Von HerrathSummaryAffiliation: La Jolla Institute for Allergy and Immunology Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3Alusha A Mamchak
Entelos Inc, Foster City, California, USA
Diabetes 61:1490-9. 2012....
Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgammaG Fousteri
Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Diabetologia 53:1958-70. 2010..Here we analysed the effect of B:9-23/IFA immunisation at later stages of the disease and the underlying mechanisms...
Type 1 diabetes as a relapsing-remitting disease?Matthias von Herrath
La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California 92037, USA
Nat Rev Immunol 7:988-94. 2007..Here, we propose that the immunological process that is at the root of T1D is relapsing-remitting in nature and discuss the unresolved controversies and therapeutic implications of this hypothesis...
Vaccination to prevent type 1 diabetesMatthias G Von Herrath
La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, San Diego, CA 92121, USA
Expert Rev Vaccines 1:25-8. 2002..Both will be discussed in this chapter and suitable combinatorial approaches will be suggested...
Introducing baselines for therapeutic use of regulatory T cells and cytokines in autoimmunityMatthias von Herrath
La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121 1118, USA
Trends Immunol 24:540-5. 2003..g. autoimmunity). Conversely, regulatory cells and cytokines operative at low homeostatic levels should unfold therapeutic capacities by further embellishment but not additional reduction...
How can we improve the translational landscape for a faster cure of type 1 diabetes?Matthias von Herrath
La Jolla Institute for Allergy and Immunology, California 92037, USA
J Clin Invest 119:1061-5. 2009....
Remodeling rodent models to mimic human type 1 diabetesMatthias von Herrath
Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, UCSD, La Jolla, CA 92037, USA
Eur J Immunol 39:2049-54. 2009....
Islet regeneration needed for overcoming autoimmune destruction - considerations on the pathogenesis of type 1 diabetesMatthias von Herrath
Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Pediatr Diabetes 5:23-8. 2004..The recent development of novel technologies will allow more precise quantification of in vivo destruction and regeneration in order to test these hypotheses...
Microorganisms and autoimmunity: making the barren field fertile?Matthias G Von Herrath
Division of Developmental Immunology, Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Centre Drive, San Diego, California 92121, USA
Nat Rev Microbiol 1:151-7. 2003....
Protection from type 1 diabetes in the face of high levels of activated autoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strainM G von Herrath
Immunology and Neuropharmacology, The Scripps Research Institute, La Jolla, California 92121, USA
Diabetes 50:2700-8. 2001..This finding has important implications for interpreting numbers and pathogenicity of autoreactive lymphocytes in prediabetic patients of genetically diverse backgrounds...
E1-INT (Transition Therapeutics/Novo Nordisk)Matthias von Herrath
La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, San Diego, CA 92121, USA
Curr Opin Investig Drugs 6:1037-42. 2005..The compound is currently undergoing phase II clinical trials...
Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearanceMatthias G Von Herrath
Department of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
J Immunol 168:933-41. 2002..Thus, administration of nonmitogenic CD3 prevents diabetes by sufficient systemic reduction of (auto)aggressive lymphocytes, but without compromising antiviral immune competence...
New trends in immunosuppression--sixth international congress. New drug candidates. 5-8 February 2004, Salzburg, AustriaMatthias von Herrath
Department of Neuropharmacology, Division of Virology IMM6, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
IDrugs 7:211-4. 2004
Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapiesMatthias von Herrath
Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
Diabetes 58:2-11. 2009..In combination, these two immune elements have the potential to permanently stop type 1 diabetes. It is my belief that only combination therapies will enable the permanent prevention and curing of type 1 diabetes...
Animal models of human type 1 diabetesMatthias von Herrath
Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
Nat Immunol 10:129-32. 2009..This commentary addresses the utility and limitations of these models for facilitating the 'translation' of immunology research into clinical applications...
Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunityMatthias G Von Herrath
La Jolla Institute for Allergy and Immunology, San Diego, CA 92109, USA
J Exp Med 202:1159-62. 2005....
Immunoinformatics: an overview of computational tools and techniques for understanding immune functionMatthias von Herrath
La Jolla Institute for Allergy and Immunology, Immune Regulation Lab, 9420 Athena Circle, La Jolla, CA 92037, USA
Expert Rev Clin Immunol 3:993-1002. 2007..This review addresses why in silico modeling is needed in immunology research, highlights some of the major areas of research and suggests what may be important for the future of immunoinformatics...
SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetesAna Maria Barral
La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Autoimmun 27:166-73. 2006..Thus, SOCS expression renders beta-cells resistant to CTL attack in a mouse model of T1D...
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunityChristophe M Filippi
La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
Diabetes 57:2684-92. 2008..We investigated the differential effect of this cytokine on CD8(+) T-cells in autoimmunity and antiviral immunity...
A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetesUrs Christen
Immune Regulation Lab, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
J Clin Invest 114:1290-8. 2004..Sequential heterologous viral infections might therefore act in concert to precipitate clinical autoimmune disease, even if single exposure to a viral mimic does not always cause sufficient tissue destruction...
Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes developmentAntje Rhode
Immune Regulation Laboratory, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
J Immunol 175:3516-24. 2005..Our results indicate that CXCL10 expression accelerates the autoimmune process by enhancing the migration of Ag-specific lymphocytes to their target site...
Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD miceMarianne M Martinic
Immune Regulation Lab DI 3, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
Diabetes 56:1059-68. 2007..Thus, autoreactivity toward de novo-expressed beta-cell autoantigens will not accelerate autoimmunity unless large numbers of antigen-experienced autoreactive T-cells expressing the appropriate chemokine receptors are present...
Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infectionDiane Rottembourg
La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Immunol 184:7100-7. 2010..These results suggest that the TLR9 signaling pathway is involved in the efficacy of plasmid vaccination; therefore, it should remain a focus in the development or amelioration of vaccines to treat infections in humans...
CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursorsLoui T Madakamutil
La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Science 304:590-3. 2004..Thus, memory precursors can be identified among primary effector cells and are selected for survival and differentiation by CD8alphaalpha...
TLR2 signaling improves immunoregulation to prevent type 1 diabetesChristophe M Filippi
La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Eur J Immunol 41:1399-409. 2011..We identify novel mechanisms by which TLR2 promotes immunoregulation and controls autoimmune diabetes in naïve or infected hosts. This work should help understand T1D etiology and develop novel immune-based therapeutic interventions...
Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cellsUrs Christen
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California, USA
Diabetes 53:591-6. 2004..Expression of Fas-L therefore might not be protective in situations in which viral inflammation can be expected, resulting in Fas induction on the targeted cell itself...
T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetesAmy E Juedes
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA 92121, USA
J Exp Med 199:1153-62. 2004..This observation points toward a therapeutic opportunity for the treatment of T1D and other autoimmune disorders...
Virally induced inflammation and therapeutic avenues in type 1 diabetesUrs Christen
Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Endocrinol Metab Clin North Am 33:45-58, viii. 2004
Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune diseaseUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
J Immunol 171:6838-45. 2003....
Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesisMarianne M Martinic
Type 1 Diabetes Center at the La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Autoimmun 35:404-13. 2010..Therefore, autoantigens such as insulin that are expressed at higher levels in beta cells might have a more profound impact on diabetes pathogenesis...
No significant CTL cross-priming by dendritic cell-derived exosomes during murine lymphocytic choriomeningitis virus infectionKen Coppieters
Immune Regulation Laboratory DI 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Immunol 182:2213-20. 2009..Thus, DC-derived exosomes do not appear to contribute significantly to CTL priming during acute LCMV infection...
Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic isletsTom L Van Belle
Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Immunity 36:1060-72. 2012..We conclude that IL-21R controls both antigen transport by DCs and the crucial beacon function of CD4(+) cells for autoreactive CD8(+) cells to reach the islets...
Resolution of a chronic viral infection after interleukin-10 receptor blockadeMette Ejrnaes
Immune Regulation Lab DI3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Exp Med 203:2461-72. 2006..Therapeutic IL-10R blockade broke the cycle of IL-10-mediated immune suppression, preventing IL-10 priming by CD8alpha- DCs and enhancing antiviral responses and thereby resolving infection without causing immunopathology...
Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodiesRenaud Burrer
Molecular and Integrative Neurosciences Department, The Scrips Research Institute, La Jolla, CA 92037, USA
Am J Pathol 170:557-66. 2007..Our study illustrates the possibility that infections can lead to much more profound immunopathology in the presence of an otherwise latent autoimmune condition...
Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infectionTom Wolfe
Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
J Immunol 169:4867-72. 2002..In terms of safety it is encouraging that resolution of the infection, at least in the case of LCMV, is not inhibited...
IP-10 and type 1 diabetes: a question of time and locationUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
Autoimmunity 37:273-82. 2004....
IP-10 and type 1 diabetes: a question of time and locationUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA, USA
Autoimmunity 37:273-82. 2004....
Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradientUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
J Clin Invest 113:74-84. 2004..Thus, virally induced proinflammatory cytokines and chemokines can influence the ongoing autoaggressive process beneficially at the preclinical stage, if produced at the correct location, time, and levels...
Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced modelTom L Van Belle
Diabetes Center of San Diego, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Immunol 187:2915-22. 2011..We conclude that viral elimination and type 1 diabetes can occur in the absence of detectable IL-17A production, suggesting IL-17A is not essential in these settings...
Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatmentTom L Van Belle
Diabetes Center at San Diego, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
J Autoimmun 34:445-52. 2010....
CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cellsDirk Homann
Department of Neuropharmacology, Division of Virology, The Scripps Research Institute, La Jolla, CA 92037, USA
Immunity 16:403-15. 2002..Furthermore, protection of prediabetic recipients was autoantigen specific and did not result in generalized immunosuppression. The origin, function, and therapeutic potential of these bitypic NK/DC regulatory cells is discussed...
Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse modelUrs Christen
Department of Immune Regulation, IR-3, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
Transgenic Res 11:587-95. 2002....
Manipulating the type 1 vs type 2 balance in type 1 diabetesUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
Immunol Res 30:309-25. 2004..In this review we will focus on the pathogenesis of T1D in a virus-induced transgenic mouse model and discuss possibilities of how an aggressive type 1-dominated immune response can be restrained and autoimmunity be abrogated...
Viral infections and molecular mimicry in type 1 diabetesKen T Coppieters
Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
APMIS 120:941-9. 2012..In this review, we will take a closer look at mechanistic evidence for a potential role of viruses in T1D, with a special focus on molecular mimicry...
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytesEdith M Janssen
Division of Cellular Immunology and Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, California 92121, USA
Nature 421:852-6. 2003..Our results demonstrate that T-cell help is 'programmed' into CD8+ T cells during priming, conferring on these cells a hallmark of immune response memory: the capacity for functional expansion on re-encounter with antigen...
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodiesMette Ejrnaes
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
Clin Dev Immunol 13:337-47. 2006..First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes...
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patientsKen T Coppieters
Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Exp Med 209:51-60. 2012..Our observations provide the first direct proof for islet autoreactivity within human islets and underscore the heterogeneous and chronic disease course...
Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in miceChristophe M Filippi
La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
J Clin Invest 119:1515-23. 2009..Our results provide what we believe to be novel mechanistic insight into the role of viruses in T1D and should be valuable for prospective studies in humans...
Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominanceMaya F Kotturi
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Immunol 181:2124-33. 2008..Thus, our results indicate that an intrinsic property of the epitope (MHC binding affinity) and an intrinsic property of the host (naive precursor frequency) jointly dictate the immunodominance hierarchy of CD8(+) T cell responses...
Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the autoimmune process is already ongoingUrs Christen
Departments of Neuropharmacology and Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
Ann N Y Acad Sci 958:166-9. 2002..Here we provide a model of how experienced autoaggressive CD8 lymphocytes are dying by apoptosis as a result of beta cell-specific TNF-alpha expression at a time when the autoimmune process is already ongoing...
Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristicsMette Ejrnaes
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
J Immunol 174:2746-55. 2005..Thus, secretion of IFN-gamma-inducible protein-10 by autoaggressive CD8(+) lymphocytes might determine their diabetogenic capacity by affecting recruitment of cells to the insulitic lesion...
Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safetyTom Wolfe
Departments of Neuropharmacology and Immunology, The Scripps Research Institute, La Jolla, CA, USA
Eur J Immunol 32:113-21. 2002..Our findings will be of importance for designing safe antigen-specific interventions for human type 1 diabetes...
Rational development of antigen-specific therapies for type 1 diabetesGeorgia Fousteri
La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, La Jolla, CA, USA
Adv Exp Med Biol 601:313-9. 2007....
Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditisGeorgia Fousteri
Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
J Autoimmun 36:210-20. 2011..Altogether, these results chart the way for novel prevention and intervention strategies for viral myocarditis...
Cure of chronic viral infection by neutralizing antibody treatmentMette Ejrnaes
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
Autoimmun Rev 6:267-71. 2007....
Induction, acceleration or prevention of autoimmunity by molecular mimicryUrs Christen
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA 92121, USA
Mol Immunol 40:1113-20. 2004..Already activated autoreactive cells might be easier re-activated and primed for effector functions by cross-reactive ligands than naive lymphocytes...
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodiesMette Ejrnaes
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
Clin Dev Immunol 13:67-77. 2006..First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes...
Regulation of viral and autoimmune responsesChrystelle Asseman
La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, 10355, Science Center Drive, San Diego, CA 92121, USA
Novartis Found Symp 252:239-53; discussion 253-67. 2003..However, we have recent evidence that virus specific CD25+ cells can be generated and are able to affect antiviral responses in vivo...
Cytokines and chemokines in virus-induced autoimmunityUrs Christen
The Scripts Research Institute, Division of Virology, La Jolla, California, USA
Adv Exp Med Biol 520:203-20. 2003
Regulatory T-cells in type 1 diabetesAmy E Juedes
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
Diabetes Metab Res Rev 20:446-51. 2004..This review will concentrate on two different types of regulatory T-cells, the naturally occurring ('professional') CD4+CD25+ T-cells and antigen-induced ('adaptive') CD4+ Th2-like regulatory T-cells...
Initiation of autoimmunityUrs Christen
Immune Regulation Laboratory, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, California 92121, USA
Curr Opin Immunol 16:759-67. 2004....
Novel strategies to eliminate persistent viral infectionsMarianne M Martinic
La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
Trends Immunol 29:116-24. 2008..We discuss how future combination therapies can be used to inhibit viral synthesis as well as strengthen the antiviral response without increasing immunopathology or the development of autoimmune disease...
Autoantibodies exacerbate the severity of MHV-induced encephalitisRenaud Burrer
The Scripps Research Institute, La Jolla, California, USA
Adv Exp Med Biol 581:399-402. 2006
Islet beta-cell death - fuel to sustain autoimmunity?Christophe M Filippi
La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
Immunity 27:183-5. 2007..2007) find that secondary necrosis of beta-cells can prime the autoimmune response via uptake by and activation of antigen-presenting cells through Toll-like receptor 2...
Control of graft-versus-host disease by regulatory T cells: which level of antigen specificity?Marianne M Martinic
Immune Regulation Lab, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Eur J Immunol 36:2299-303. 2006..Such ideal interventions will hopefully retain a diverse repertoire of pathogen-specific T cells, while maintenance of self-, foreign- and alloantigen-specific Tregs ensures life-long graft tolerance...
Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetesDamien Bresson
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
Mol Ther 18:307-16. 2010..Our findings hold important implications to understand and predict the success of antigen-based clinical trials, where responsiveness to immunotherapy might vary from patient to patient...
Antigen-specific induction of regulatory T cells for type 1 diabetes therapyChristophe Filippi
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
Int Rev Immunol 24:341-60. 2005....
How viral infections affect the autoimmune process leading to type 1 diabetesChristophe Filippi
La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Cell Immunol 233:125-32. 2005....
CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetesGeorgia Fousteri
Diabetes Center, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
J Autoimmun 32:70-7. 2009..While in cases of rapid microbial (CD8)-driven T1D CD103 antibody blockade may not limit disease progression or severity, in mucosally-driven cases of T1D anti-CD103 antibody treatment may provide a new and safe therapeutic avenue...
Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantationGeorgia Fousteri
La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
Regen Med 2:845-51. 2007..This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes...
Mucosal exposure to antigen: cause or cure of type 1 diabetes?Georgia Fousteri
La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 9420 Athena Circle, La Jolla, CA 92037, USA
Curr Diab Rep 7:91-8. 2007....
Type 1 diabetes: etiology, immunology, and therapeutic strategiesTom L Van Belle
Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
Physiol Rev 91:79-118. 2011..In this comprehensive review, we explain the genetic, environmental, and immunological data underlying the prevention and intervention strategies to constrain T1D...
Antigen-induced regulatory T cells in autoimmunityMatthias G Von Herrath
La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, 10355 Science Center Drive, San Diego, California 92121, USA
Nat Rev Immunol 3:223-32. 2003..In this review, we consider the nature and function of such antigen-specific T(Reg) cells, and strategies for their therapeutic induction are discussed...
Pathogenesis of type 1 diabetes: a viewpointMatthias G Von Herrath
La Jolla Institute for Allergy and Immunology, San Diego, California, USA
Adv Exp Med Biol 552:317-21. 2004
Infections and autoimmunity--good or bad?Urs Christen
Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
J Immunol 174:7481-6. 2005..Knowledge of mechanisms that underlie either positive or negative effects of infections on autoimmunity will facilitate exploration of molecular details for prospective clinical studies in the future...
The role of the activating receptor NKG2D in autoimmunityTom L Van Belle
Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Mol Immunol 47:8-11. 2009..In this review, we discuss the current knowledge on NKG2D and its ligands in the context of autoimmune diseases and immune-mediated diseases that inadvertently target endogenous cells and/or tissue...
Real-time imaging of the pancreas during development of diabetesMarianne M Martinic
Immune Regulation Laboratory DI 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Immunol Rev 221:200-13. 2008..Understanding the cellular dynamics during T1D development is critical for the rational design of immunotherapies...
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsDamien Bresson
Department of Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
J Clin Invest 116:1371-81. 2006..Since Tregs act site-specifically, this strategy should also be expected to reduce the potential for systemic side effects...
Progress in the development of immune-based therapies for type 1 diabetes mellitusMatthias von Herrath
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
BioDrugs 20:341-50. 2006..There are, however, a number of concerns that should be addressed in order to improve future therapeutic strategies...
Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individualsKen T Coppieters
Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Diabetes Metab Res Rev 27:746-54. 2011..It remains questionable, however, whether these surviving cells can physiologically sense and respond to glucose stimuli...
Immunosuppression in islet transplantationTom Van Belle
La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
J Clin Invest 118:1625-8. 2008..Reemergence of autoreactivity is likely the main culprit underlying long-term islet graft failure, and new strategies will need to be tested to circumvent this homeostatic expansion and recurrent autoreactivity...
First-trimester human fetal pancreas transplantation for type 1 diabetes treatment: an alternative approach for achieving long-term graft survival?Georgia Fousteri
La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
Diabetes 57:525-6. 2008
Resuscitating adaptive Tregs with combination therapies?Damien Bresson
Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Novartis Found Symp 292:50-60; discussion 60-7, 122-9, 202-3. 2008....
Using regulatory APCs to induce/maintain toleranceAmy E Juedes
Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
Ann N Y Acad Sci 1005:128-37. 2003....
Immune responsiveness, tolerance and dsRNA: implications for traditional paradigmsMatthias G Von Herrath
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
Trends Immunol 24:289-93. 2003..Accumulating evidence on the immunomodulatory roles of dsRNAs warrants a reconsideration of various models of immune homeostasis...
Minimal effect of CD103 expression on the control of a chronic antiviral immune responseGeorgia Fousteri
Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
Viral Immunol 23:285-94. 2010..Thus, a lack of CD103 expression does not affect functional impairment of effector T-cell responses during chronic viral infection...
Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune pathologyAdrian Bot
Department of Immunology and Cancer Research, MannKind Corporation, Valencia, California, USA
DNA Cell Biol 23:341-50. 2004..Finally, we outline implications on the earlier concept of T1/T2 dichotomy, supporting a model in which these two subsets, rather than being mutually antagonistic, together facilitate the recovery from infection...
Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivoClaus Haase
Hagedorn Research Institute, Niels Steensens Vej 6, DK-2820 Gentofte, Denmark
Blood 106:4225-33. 2005....
Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchyMark K Slifka
Oregon Health and Science University Vaccine and Gene Therapy Institute, Beaverton, OR 97006, USA
J Immunol 170:1231-9. 2003..By allowing the escape of subdominant T cells, this process still preserves a relatively broad peripheral TCR repertoire that can actively participate in antiviral and/or autoreactive immune responses...
Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune diseaseRobert S Fujinami
Department of Neurology, University of Utah School of Medicine, 30 N 1900 E, 3R330 SOM, Salt Lake City, UT 84132 2305, USA
Clin Microbiol Rev 19:80-94. 2006..These mechanisms are discussed in the context of multiple sclerosis, myocarditis, and diabetes, three immune-medicated diseases often linked with virus infections...
The role of innate immunity in autoimmunityJean Francois Bach
INSERM U580, Hopital Necker, Paris, France
J Exp Med 200:1527-31. 2004....
Interfacing dendritic and natural killer cells: a tool for targeted tolerance induction?Dirk Homann
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO, USA
Transplantation 76:1657-61. 2003
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesionsCatherine B Renard
Department of Pathology, University of Washington, Seattle, Washington, USA
J Clin Invest 114:659-68. 2004..Thus, diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions...
Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunityDirk Homann
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center Mail stop B140, P O Box 6511, Aurora, CO 80045, USA
J Virol 80:270-80. 2006..These findings have implications for the physiologic, pathological, and therapeutic regulation of costimulation...
Research Grants
- DNA Vaccination & Regulatory Cells in Type I DiabetesMatthias von Herrath; Fiscal Year: 2003..abstract_text> ..
- Role of a Non-Tolerant Autoantigen in AutoimmunityMatthias von Herrath; Fiscal Year: 2007..abstract_text> ..
- Animal Models in Type 1 Diabetes and Multiple SclerosisMatthias von Herrath; Fiscal Year: 2006..Additionally, we expect that this symposium will be of interest to junior faculty working in the areas of autoimmune disease research, as well as patient advocacy groups. ..
- Achieving Therapeutic Antigent-Specific Tolerance in Type 1 DiabetesMatthias von Herrath; Fiscal Year: 2007..These assays should provide strong guidance to the goals of the clinical project (#3, Herold). ..
- CXCR3 Chemokines in Type I DiabetesMatthias von Herrath; Fiscal Year: 2009..Aim 1: Importance of IP-10 in the pathogenesis of T1D - therapeutic blockade and mechanistic analyses. Aim 2: Importance of IP-10 during islet allograft rejection - therapeutic blockade and mechanistic analyses. ..
- How IL-10R blockade can resolve persistent viral infectionsMatthias G Von Herrath; Fiscal Year: 2010..In order to assure that our findings reach those groups working on HIV and HCV, cooperations have been established with leading groups in the field. ..
- Role of a Non-Tolerant Autoantigen in AutoimmunityMatthias von Herrath; Fiscal Year: 2006..abstract_text> ..
- Role of a Non-Tolerant Autoantigen in AutoimmunityMatthias von Herrath; Fiscal Year: 2003..We believe that these two goals will greatly improve our understanding of how autoantigens are driving an autoaggressive process and during which phases of the diabetogenic response the initiating antigen(s) are important. ..
- IMMUNE TOLERANCE INDUCTION BY APOPTOTIC BODIESMatthias von Herrath; Fiscal Year: 2005..abstract_text> ..
- How Does blockade of CD40/CD40L Prevent Autoimmunity?Matthias von Herrath; Fiscal Year: 2005..Therefore, the direct comparison of three autoimmune models will enable us to define, which in vivo consequences of costimulation blockade occur more commonly and which are restricted to a given experimental situation. ..
- DNA Vaccination & Regulatory Cells in Type I DiabetesMatthias von Herrath; Fiscal Year: 2006..abstract_text> ..
- How IL-10R blockade can resolve persistent viral infectionsMatthias von Herrath; Fiscal Year: 2009..In order to assure that our findings reach those groups working on HIV and HCV, cooperations have been established with leading groups in the field. ..
